Kiniksa Pharmaceuticals, Ltd. (NASDAQ: KNSA) reported Q3 EPS of ($0.18), $0.19 worse than the analyst estimate of $0.01. Revenue for the quarter came in at $112.21 million versus the consensus estimate of $110.29 million.

For earnings history and earnings-related data on Kiniksa Pharmaceuticals, Ltd. (KNSA) click here.